id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-D-2565-0030,FDA,FDA-2016-D-2565,Draft Guidance for Industry and FDA_510(k) Third Party Review Program and Third Party EUA Reivew,Other,Guidance,2023-12-22T05:00:00Z,2023,12,2023-12-22T05:00:00Z,2024-02-21T04:59:59Z,2024-11-21T14:13:13Z,,0,0,090000648634e6c9
FDA-2016-D-2565-0029,FDA,FDA-2016-D-2565,"510(k) Third Party Review Program and Third Party Emergency Use
Authorization (EUA) Review; Draft Guidance for Industry, Food and Drug
Administration Staff, and Third Party Review Organizations; Availability",Notice,Notice of Availability,2023-12-21T05:00:00Z,2023,12,,,2023-12-21T17:23:07Z,2023-28095,0,0,090000648634e286
FDA-2016-D-2565-0028,FDA,FDA-2016-D-2565,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2023-02-14T05:00:00Z,2023,2,2023-02-14T05:00:00Z,,2023-02-14T14:49:38Z,2023-03073,0,0,0900006485693529